LODINE
ETODOLAC
Approval overview LODINE is listed in Drugs@FDA under application 018922 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient ETODOLAC Form and strength CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor WYETH PHARMS INC Submission history Latest submission status date: 2007-10-11 00:00:00.
Structured Monograph
Clinical summary
Approval overview LODINE is listed in Drugs@FDA under application 018922 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ETODOLAC Form and strength CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor WYETH PHARMS INC Submission history Latest submission status date: 2007-10-11 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.